<DOC>
	<DOCNO>NCT01888835</DOCNO>
	<brief_summary>The investigator recently conduct double-blind , randomize control trial ( n=60 ) limit duration ( 12 week ) , find compare placebo , oral mirtazapine , FDA-approved antidepressant , significantly reduce meth use receive mirtazapine , determine reduction meth-positive urine . Sexual risk behavior also decline significantly mirtazapine arm compare placebo . Mirtazapine decrease meth use despite low adherence : medical event monitoring system ( MEMS ) cap , 48.5 % daily dose take . All participant receive weekly substance use counsel monthly , brief clinician-delivered adherence counseling . The investigator propose expand upon result lengthen treatment period 24 week , adherence reminder add counseling , determine efficacy sustain 12 week drug discontinuation . The sample size 9-month study 120 .</brief_summary>
	<brief_title>Mirtazapine Treatment Methamphetamine Dependence Among MSM ( M2.0 )</brief_title>
	<detailed_description />
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>1. born male , born female identify female ; 2. report anal sex men prior three month influence meth ; 3. diagnose meth dependence SCID ; 4. interested stop reduce meth use ; 5. least one methpositive urine screen runin period ; 6. current acute illness require prolong medical care ; 7. serious chronic illness likely progress clinically trial participation ; 8. able willing provide inform consent adhere visit schedule ; 9. age 1869 year ; 10. baseline CBC , total protein , albumin , glucose , alkaline phosphatase , creatinine , BUN , electrolytes without clinically significant abnormality determine clinician conjunction symptom , physical exam , medical history 11. current CD4 count â‰¥ 200 cells/mm3 ; CD4 count 100 199 cells/mm3 HIV viral load &lt; 200 copies/mL 12. textcapable cell phone access email 1 . Evidence current major depression SCID ; 2. history bipolar disorder psychotic disorder , determine SCID ; 3. know allergy previous adverse reaction mirtazapine ; 4. take antidepressant medication within past 30 day , include mirtazapine monoamineoxidase inhibitor ; 5. moderate severe liver disease ( AST , ALT , total bilirubin &gt; = 5 time upper limit normal ) ; 6. impair renal function ( estimate GFR &lt; 40 ml/min ) ; 7. currently participate another research study ; 8. pending legal proceeding high risk incarceration time plan study participation ; 9. condition , principal investigator 's judgment , interfere safe study participation adherence study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>sexual behavior</keyword>
</DOC>